Search
Research
Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinomaThis study contributes to our understanding of the genetic diversity of NMC, an important step towards finding therapeutic targets for a disease that is...
Research
Maternal Use of Folic Acid and Other Supplements and Risk of Childhood Brain TumorsInterest in a possible protective effect of maternal vitamin use before or during pregnancy against childhood brain tumors (CBT) and other childhood cancers...
Research
Participation in population-based case-control studies: Does the observed decline vary by socio-economic status?An Australian study of childhood leukaemia (Aus-ALL) previously reported that control participation was positively associated with socio-economic status...
News & Events
The Kids Research Institute Australia researchers share in State Government science grantsFour The Kids Research Institute Australia researchers are among those who have received funding in the WA State Government's Merit Award Program announced today.
News & Events
New drug hope for babies with leukaemiaResearchers at The Kids Research Institute Australia have discovered a new drug combination that could help improve survival rates for babies with leukaemia.
News & Events
A cell change that drives leukaemiaIt is now known that the HOX11 gene is permanently activated in the leukaemia cells and it drives the disease.
News & Events
WA families to help find triggers for childhood leukaemiaWest Australian families are being asked to play a vital role in a major new national study to unravel the causes of childhood leukaemia.
Research
Psychosocial Outcomes in Parents of Children with Acute Lymphoblastic Leukaemia in Australia and New Zealand Through and Beyond TreatmentParents of children with acute lymphoblastic leukaemia (ALL) experience emotional distress throughout their child's treatment course. This study describes the psychological experience of Australian and New Zealand parents of children diagnosed with ALL.
Research
Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179OLIG2-expressing tumor stem cells have been shown to drive recurrence in Sonic Hedgehog (SHH)-subgroup medulloblastoma (MB) and patients urgently need specific therapies to target this tumor cell population.
Research
Fc-Engineered B7-H3 Antibody with Prolonged Serum Half-Life for Enhanced Cancer TherapyMonoclonal antibodies are revolutionizing the landscape of current cancer treatment, bringing hope to patients with incurable cancers. B7-H3 (CD276) is an attractive therapeutic target for antibody-based therapy due to its low or absent expression in normal tissues and high expression in various types of tumors, including prostate cancer, pancreatic cancer, and high-mortality esophageal squamous cell carcinoma (ESCC). In recent years, various B7-H3-targeting antibodies have been developed for cancer treatment, with a few making their way to clinical trials.